StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research report report published on Wednesday morning. The firm issued a sell rating on the stock.

Oragenics Price Performance

Oragenics stock opened at $0.27 on Wednesday. The stock has a market cap of $3.35 million, a price-to-earnings ratio of -0.04 and a beta of 0.49. The firm has a 50-day moving average of $0.37 and a two-hundred day moving average of $1.01. Oragenics has a 1 year low of $0.25 and a 1 year high of $7.74.

Institutional Investors Weigh In On Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC acquired a new stake in Oragenics, Inc. (NYSE:OGEN) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics at the end of the most recent reporting period. Institutional investors and hedge funds own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.